Bio­gen fi­nal­ly pub­lish­es PhI­II re­sults for Aduhelm as crit­ics chas­tise low-rank­ing jour­nal, ‘gen­tle and un­re­veal­ing’ peer re­view

Bio­gen qui­et­ly an­nounced at a con­fer­ence in Spain to­day that a man­u­script of the Phase III re­sults for the com­pa­ny’s con­tro­ver­sial Alzheimer’s drug Aduhelm has fi­nal­ly been pub­lished in a tiny jour­nal with a con­flict­ed chief ed­i­tor, al­most a year af­ter the drug won its ac­cel­er­at­ed ap­proval.

The man­u­script was pub­lished Wednes­day in the Jour­nal of Pre­ven­tion of Alzheimer’s Dis­ease, a spokesper­son told End­points News, point­ing to the re­lease’s link to a com­pa­ny pre­sen­ta­tion to­day at the 2022 In­ter­na­tion­al Con­fer­ence on Alzheimer’s and Parkin­son’s Dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER